Kong Dehua, Gao Chunyan, Yu Yang, Yang Lu, Ma Ji, Tang Shimin, Mao Ying, Li Yong, Li Na
Department of Oncology, Suining Central Hospital, Suining City, China.
Department of Oncology and Hematology, Shenzhen Pingshan District Central Hospital, Shenzhen City, China.
PLoS One. 2025 Jun 30;20(6):e0325349. doi: 10.1371/journal.pone.0325349. eCollection 2025.
This study aims to elucidate the distribution patterns of immune cells associated with the programmed cell death protein 1 (PD-1) pathway within esophageal cancer (EC) tissues and to determine their correlation with patient prognosis.
We included tissue samples from 236 EC patients who had undergone surgery at our institution between January 2016 and January 2021. This study examined the correlation between six immunohistochemical markers and the clinical profiles of these patients. Survival analysis was performed using the Kaplan-Meier method and the LOG-rank test to evaluate the impact of immunohistochemical marker expression on patient survival. A clinical predictive model was developed and validated for prognostic assessment.
Expression levels of PD-1, PD-L1, FOXP3, and CD25 were found to be positively associated with the depth of tumor invasion and lymph node metastasis (P < 0.05). In contrast, CD4 and CD8 expression levels were inversely related to these parameters (P < 0.05). High expression of PD-1, PD-L1, FOXP3, and CD25, along with lymph node metastasis, were identified as independent prognostic risk factors (P < 0.05). Patients with low expression of PD-1, PD-L1, FOXP3, CD25, and high expression of CD4 and CD8 exhibited improved three-year survival rates (P < 0.001). The predictive model, based on these factors, demonstrated high discrimination and accuracy.
A prognostic model incorporating the expression levels of PD-1, PD-L1, FOXP3, CD25, and lymphocyte infiltration offers robust predictive validity for the prognosis of EC patients.
本研究旨在阐明食管癌(EC)组织中与程序性细胞死亡蛋白1(PD-1)通路相关的免疫细胞分布模式,并确定它们与患者预后的相关性。
我们纳入了2016年1月至2021年1月期间在我院接受手术的236例EC患者的组织样本。本研究检测了六种免疫组化标志物与这些患者临床特征之间的相关性。采用Kaplan-Meier法和对数秩检验进行生存分析,以评估免疫组化标志物表达对患者生存的影响。开发并验证了一种临床预测模型用于预后评估。
发现PD-1、PD-L1、FOXP3和CD25的表达水平与肿瘤浸润深度和淋巴结转移呈正相关(P < 0.05)。相比之下,CD4和CD8的表达水平与这些参数呈负相关(P < 0.05)。PD-1、PD-L1、FOXP3和CD25的高表达以及淋巴结转移被确定为独立的预后危险因素(P < 0.05)。PD-1、PD-L1、FOXP3、CD25低表达且CD4和CD8高表达的患者三年生存率有所提高(P < 0.001)。基于这些因素的预测模型显示出较高的区分度和准确性。
一个包含PD-1、PD-L1、FOXP3、CD25表达水平和淋巴细胞浸润的预后模型对EC患者的预后具有强大的预测效度。